Efficacy of Hydroxyurea in Transfusion-Dependent Major β-Thalassemia Patients: A Meta-Analysis-Reference-Cited by-同舟云学术

Efficacy of Hydroxyurea in Transfusion-Dependent Major β-Thalassemia Patients: A Meta-Analysis

Published:2023-04-26 Issue: Volume: Page:
ISSN:2168-8184
Container-title:Cureus
language:en
Short-container-title:

Author:

Hatamleh Modather I,Chenna Venkata Sai Harshabhargav,Contractor Hazel,Krishna Mohan Gautham Varun,Tirumandyam Gayathri,Dammas Nada,Khan Muhammad Waqas,Hirani Shamsha

Publisher

Springer Science and Business Media LLC

Subject

Aerospace Engineering

Reference23 articles.

1. The thalassaemia syndromes;Weatherall DJ,2008

2. β-Thalassemias;Taher AT;N Engl J Med,2021

3. A paradigm shift on beta-thalassaemia treatment: how will we manage this old disease with new therapies?;Cappellini MD;Blood Rev,2018

4. Hemopoietic stem cell transplantation in thalassemia: a report from the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Registry, 2000-2010;Baronciani D;Bone Marrow Transplant,2016

5. Editing an α-globin enhancer in primary human hematopoietic stem cells as a treatment for β-thalassemia;Mettananda S;Nat Commun,2017

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current advances in 2024: A critical review of selected topics by the Association for the Advancement of Blood and Biotherapies (AABB) Clinical Transfusion Medicine Committee;Transfusion;2024-08

2. Unraveling Impact of Hemoglobin F and A2 Levels: Correlation With Disease Severity and Treatment Response in Transfusion-Dependent Beta-Thalassemia;Cureus;2024-01-10

3. Inhibitory effects of SARS-CoV-2 spike protein and BNT162b2 vaccine on erythropoietin-induced globin gene expression in erythroid precursor cells from patients with β-thalassemia;Experimental Hematology;2024-01

4. New Synthetic Isoxazole Derivatives Acting as Potent Inducers of Fetal Hemoglobin in Erythroid Precursor Cells Isolated from β-Thalassemic Patients;Molecules;2023-12-19

5. Gene Therapy for Hemoglobinopathies;Human Gene Therapy;2023-09-01